Merdan S, Barnett CL, Denton BT, Montie JE, Miller DC. OR practice–data analytics for optimal detection of metastatic prostate cancer. Oper Res. 2021 May;69(3):2-4. doi: 10.1287/opre.2020.2020
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Nabbout R, Auvin S, Cross JH, Guerrini R, Scheffer I, Thiele E, Chiron C, Irwin J, Mistry A, Williamson N, Grimes R, Bennett B. Cultural relevance of the global impact of Dravet Syndrome in Australia, Italy, the US and UK. Eur J Paediatr Neuro. 2017 Jun 1;21(Suppl 1):E187. doi: 10.1016/j.ejpn.2017.04.777
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Grzywacz JG, Quandt SA, Early J, Tapia J, Graham CN, Arcury TA. Leaving Family for Work: ambivalence and Mental Health Among Mexican Migrant Farmworker Men. J Immigr Minor Health. 2006 Jan 1;8(1):85-97.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.